- Labeled
- 10 mg
- Measured
- 9.8 mg
- Identity
- Confirmed
CJC (No Dac) + Ipamorlin
$89.00
99%+ Purity
A growth hormone secretagogue blend pairing the GHRH analog CJC (No Dac) with the selective ghrelin receptor agonist Ipamorlin for GH-axis research.
- CJC (No Dac) (No DAC)—5mg
- Ipamorlin—5mg
Every batch, independently tested.
Each lot is analysed by a third-party laboratory. The results below are from the certificate for this exact lot — not a representative sample.
| Parameter | Result | Method | Specification |
|---|---|---|---|
| Identity | 2-peptide blend · Pass | UPLC/MS | Confirmed |
| Appearance | White lyophilized powder | Visual | Meets spec |
| Purity (lowest component) | 99.28% · Pass | UPLC/MS | > 98% |
| Net peptide content (total) | 9.8 mg | UPLC/MS | 10 mg |
Each compound in this blend, tested separately
| Compound | Purity | Labeled | Measured |
|---|---|---|---|
| Ipamorlin | 99.28% · Pass | 5 mg | 4.9 mg |
| CJC (No Dac) no DAC | 99.36% · Pass | 5 mg | 4.9 mg |
Lot P-3823790 · analysed May 9, 2026 · Horizon Analytical

Certificate of Analysis
Third-party tested for purity
- Labeled
- 10 mg
- Measured
- 10.08 mg
- Identity
- Confirmed
- Labeled
- 10 mg
- Measured
- 9.87 mg
- Identity
- Confirmed
Research Overview
The CJC (No Dac)/Ipamorlin combination pairs two distinct growth hormone secretagogues that engage complementary receptor pathways on pituitary somatotroph cells. CJC (No Dac) (No DAC) is a modified growth hormone-releasing hormone (GHRH) analog: the tetrasubstituted GHRH(1-29) peptide of CJC (No Dac) without its albumin-binding linker (Jetté et al., Endocrinology 2005, in rat pituitary cells and rats; the lot certificate identifies the component by this name and formula). Ipamorlin is a selective pentapeptide ghrelin receptor (GHS-R1a) agonist with minimal effect on ACTH, cortisol, or prolactin — a selectivity profile that distinguishes it from other growth hormone secretagogues like GHRP-6 and GHRP-2. Together, they activate two independent axes of GH release signaling.
Dual-Axis Synergy Mechanism
Researchers investigate this combination to study dual-axis GH stimulation. The reference finding that concurrent GHRH and ghrelin-receptor activation releases more GH than either alone comes from a study in healthy men (Bowers et al., J Clin Endocrinol Metab 1990); in laboratory models the interaction is species-dependent — more than additive in rat pituitary cells but only additive in bovine cells (Rico et al., J Physiol Biochem 1999). The interaction is attributed to distinct intracellular signaling cascades: GHRH receptor activation primarily drives cAMP/PKA pathways on somatotroph cells, while GHS-R1a engages IP3/DAG and intracellular calcium mobilization through Gq-protein coupling. Researchers characterize the combined secretory response in terms of pulse amplitude, pulse frequency, and total GH output over time.
Comparative Studies in the GH Axis
The combination is compared against single-pathway compounds like Tesa (GHRH analog only) and Serma (shorter-acting GHRH fragment) to isolate the contribution of ghrelin receptor co-activation. Comparisons against alternative GH-axis peptides in growth hormone research help characterize how half-life differences and receptor selectivity profiles affect GH pulsatility patterns. Ipamorlin's selectivity profile — GH release without a rise in ACTH or cortisol in swine, even at exposures more than 200-fold above its GH-releasing threshold (Raun et al., Eur J Endocrinol 1998) — makes this blend useful for studying GH signaling apart from hypothalamic-pituitary-adrenal (HPA) axis confounders.
Laboratory applications include pituitary cell stimulation assays (GH ELISA and Western blot), GH pulse profiling in ex vivo tissue models, IGF-1 pathway studies (downstream PI3K/Akt signaling), receptor binding competition experiments, cAMP and calcium signaling measurements, and receptor desensitization kinetics. The blend format ensures consistent stoichiometric ratios between both components across experiments and is supplied as lyophilized powder with Certificate of Analysis.
Sources: Raun K, et al. Eur J Endocrinol. 1998;139(5):552–561 (Ipamorlin pharmacology in rat pituitary cells, rats and swine; PubMed 9849822). Bowers CY, et al. J Clin Endocrinol Metab. 1990;70(4):975–982 (a study in healthy men; cited for the GHRH + GHRP interaction only; PubMed 2108187). Rico M, et al. J Physiol Biochem. 1999;55(1):33–39 (bovine pituitary cells; PubMed 10494658). Jetté L, et al. Endocrinology. 2005;146(7):3052–3058 (the tetrasubstituted GHRH(1-29) backbone; rat pituitary cells and rats; PubMed 15817669).
Explore the PeptidesATX Research Library for additional peptide pharmacology guides and reference resources.
Frequently researched together
Compounds studied alongside this one
Frequently Asked Questions
- What is in the CJC (No Dac)/Ipamorlin blend?
- This blend combines CJC (No Dac) (a modified GHRH analog with enhanced enzymatic stability) with Ipamorlin (a selective pentapeptide ghrelin receptor agonist). Together they activate two independent GH release pathways — GHRH receptor and GHS-R1a — commonly used in growth hormone research protocols.
- What is the ratio in this blend?
- Each vial is labeled 5 mg CJC (No Dac) and 5 mg Ipamorlin. The certificate of analysis for each lot reports the measured amount and purity of each component separately; see the certificate for the current lot on this page.
- Why combine CJC (No Dac) and Ipamorlin instead of using one alone?
- The two peptides act on different receptors: CJC (No Dac) binds the GHRH receptor (cAMP/PKA signaling) while Ipamorlin binds the ghrelin receptor GHS-R1a (IP3/DAG and calcium signaling). The classic evidence that the two pathways reinforce each other is a study in healthy men, in which a GHRH plus GHRP combination released more GH than either peptide alone (Bowers et al., J Clin Endocrinol Metab 1990); in laboratory models the interaction is species-dependent — more than additive in rat pituitary cells but only additive in bovine cells (Rico et al., J Physiol Biochem 1999). That contrast is the reason the two pathways are studied together.
- How does Ipamorlin differ from other growth hormone secretagogues like GHRP-6?
- In the original pharmacology work (Raun et al., Eur J Endocrinol 1998), Ipamorlin released GH in rats and swine with a potency similar to GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol in swine even at exposures more than 200-fold above its GH-releasing threshold, and none of the compounds altered prolactin, FSH, LH or TSH. Those are animal findings. That selectivity is why Ipamorlin is used when other pituitary hormone changes would confound a GH-axis experiment.
- How does CJC (No Dac)/Ipamorlin compare to Tesa?
- Tesa is a GHRH-pathway-only compound (44 amino acids with an N-terminal modification), while CJC (No Dac)/Ipamorlin engages both GHRH and ghrelin receptor pathways simultaneously. Researchers compare them to isolate the contribution of ghrelin receptor co-activation to GH pulse amplitude and secretion patterns.
- Where can this research compound be purchased?
- This compound is available at PeptidesATX (peptidesatx.com), a U.S.-based research peptide supplier in Austin, Texas. All orders include a Certificate of Analysis, same-day shipping Monday through Thursday, and free shipping on orders over $200.
- Do you provide a Certificate of Analysis (COA)?
- Yes. Every lot listed on this site has a Certificate of Analysis from an independent laboratory (Horizon Analytical). The certificate reports the compound’s identity and purity by UPLC/MS (specification >98%; every lot currently listed measured at or above 99.05%), the measured quantity against the labeled amount, and appearance. Most lots also have a separate endotoxin report. The certificates do not include heavy-metal, sterility, residual-solvent or microbial testing, so they are not evidence that a lot is free of every possible contaminant. Every certificate can be viewed on the COA page before purchasing.
- How should I store this peptide?
- Store lyophilized (powder) vials at −20°C or colder, dry and protected from light. This is general laboratory practice for lyophilized peptides; it is not based on a product-specific stability study. Once reconstituted, keep the solution refrigerated at 2–8°C, protected from light, and use it promptly — solutions are less stable than the powder, and how long one remains usable depends on the peptide, the diluent and handling. Avoid repeated freeze–thaw cycles.
- How long does this peptide last after reconstitution?
- We have not performed product-specific stability studies, so no fixed shelf life is claimed for a reconstituted solution. Keep it refrigerated at 2–8°C, protected from light, avoid freeze–thaw cycles, and use it promptly; discard any solution that turns cloudy or shows particles. Bacteriostatic water contains 0.9% benzyl alcohol as an antimicrobial preservative for multi-draw vials; the preservative does not slow chemical degradation of the peptide itself.
- What is your shipping policy?
- Standard same-day shipping is $7.99 on all orders placed before 4 PM CT, Monday through Thursday. Orders of $200 or more ship free. All orders ship from Austin, TX with tracking provided. We ship to all 50 US states.
All products currently listed on this site are for research purposes only. U.S. sourced. Not intended for human dosing, injection, or ingestion.




